

Ipsen & IRICoR Collaborate on Early-Stage Oncology Program

- IRICoR's approach to discovery and development dovetails perfectly with Ipsen's strategy of identifying and pursuing early-stage assets with a best-in-class value proposition.
 - The two organizations recognize the value each brings to the partnership. IRICoR appreciates Ipsen's commitment to the asset, the company's understanding of IRICoR's business model and strategy, and the clear alignment on goal. Ipsen, seeing the potential with IRICoR's oncology asset, Ipsen moved quickly to execute the deal.
 - The research team at the Institute for Research in Immunology and Cancer (IRIC) at Université de Montréal works in close collaboration with the IRIC Drug Discovery Unit's medicinal chemistry team to ensure the rapid pace of development of the program.
 - IRICoR values the seriousness with which the company approaches the asset and is confident that Ipsen will make the best efforts to make sure the molecule reaches patients.
- ***"You always want a partner who believes in the science. I'm confident that Ipsen is committed to this program, and that bodes well for our success."***
 - ***-- Steven Klein, Vice President, Business Development @IRICoR***